SecBot SecBot
8-K ·Filed Nov 5, 2026

BIOA

BioAge Labs, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 6h ago SEC0001193125-26-450008
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key near-term catalyst is QUELL-CV topline data expected in Q4 2026, which will inform dose selection and provide the first proof-of-concept readout for BGE-102 in cardiovascular risk. QUELL-DME data in H2 2027 is a longer-term catalyst. The cash runway through 2029 removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonweeks

BGE-102

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 3-5 years away. BGE-102 is in Phase 2; even with positive data, Phase 3 trials and FDA review would take several years. The QUELL-DME trial results are not expected until H2 2027.
Next catalyst
None dated

What to watchThe QUELL-CV Phase 2 topline data, expected in Q4 2026 (any day now through December), is the single most important catalyst. Positive data showing a clear dose-response on hsCRP and cardiometabolic biomarkers would validate BGE-102's best-in-class profile and likely drive a significant stock re-rating given the current depressed valuation. Negative or equivocal data would compound the sector skepticism from Novo Nordisk's failure and could pressure the stock further. QUELL-DME data in H2 2027 is a secondary catalyst.

Price Chart

Loading chart...

Executive Summary

The company completed enrollment in the QUELL-CV Phase 2 cardiovascular trial with topline data expected in Q4 2026, and dosed the first patient in the QUELL-DME Phase 2 diabetic macular edema trial. Cash and marketable securities stood at $352.3M, sufficient through 2029.

Key Financial Metrics

Revenue
$298.0K
est $1.5M · -80.1% · -85.5% YoY

Key Facts

  • Net loss of $33.5M for Q3 2026, compared to $20.2M in Q3 2025
  • Collaboration revenue of $0.3M, down from $2.1M a year ago
  • R&D expenses of $30.2M, up from $18.5M in Q3 2025
  • QUELL-CV Phase 2 trial completed enrollment; topline data expected Q4 2026
  • First participant dosed in QUELL-DME Phase 2 trial; topline results expected H2 2027
  • Cash, cash equivalents and marketable securities of $352.3M as of September 30, 2026
  • APJ agonist program IND on track for year-end 2026
  • Deep Origin collaboration reached first milestone with validated hits

Financial Impact

Net loss widened by $13.3M year-over-year to $33.5M; EPS of $0.73 loss vs $0.63 consensus; cash burn rate increased as R&D spending rose 63%

net lossepsr&d expensescash position

Risk Factors

  • QUELL-CV Phase 2 data may fail to show adequate dose-response or biomarker improvement
  • QUELL-DME Phase 2 trial carries execution risk and results are not expected until H2 2027
  • Net loss continues to widen as R&D spending increases with clinical trial activity
  • Collaboration revenue declined significantly due to a cumulative catch-up adjustment in the Novartis agreement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-450008
Document: bioa-20261105.htm0001193125-26-450008
Document: 0001193125-26-450008-index-headers.html0001193125-26-450008
Document: 0001193125-26-450008-index.html0001193125-26-450008
Document: 0001193125-26-450008.txt0001193125-26-450008
8-K Data (Synthetic)0001193125-26-450008

Track record

11 reports on BIOA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
  4. Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
  5. May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
  6. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
  7. Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
  8. Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
  9. Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
  10. Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (10h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026